

LARISSA II PROJECT

Vaccine candidate: hRVFV-4s

Type of vaccine: Live-attenuated vaccine against RVF

Stage of development: In preparation for Phase 2a clinical trial


31 Oct 2025




LARISSA I (2019-2022)

RVFV-4s vaccine (double safety)

- Split M-segment
- Main virulence factor deleted



Stability confirmed
Northern blot, PCR, NGS




Pre-clinical safety and efficacy




hRVFV-4s Phase 1 Clinical trial


Cell stacks based GMP Clinical lot




Dose escalations, n=75



Good safety profile of all dose levels




Promising dose response immunogenicity




LARISSA II (2023-2027)


Scale production





Correlates of protection



Epidemiology and outbreak response




Passive transfer



Minimal protective titer:

Surrogate?




Regulatory activities

Phase IIa

- SA from AVAREF
(Preparation for Phase 2a clinical trial, 2025)
- SA and CTA simulations with AVAREF
- Engagement of Reg. authorities in Uganda and Kenya via Clinical trial sites (KEMRI & UVRI) and FHI Clinical (CRO)
- Clinical Trial Application (CTA) to Uganda and Kenya using AVAREF platform

Phase 2a Clinical trial



- Naïve and sero+
- Effect booster

Kenya: KEMRI



Uganda: UVRI



Acknowledgements

Funding

